This site is intended for health professionals only

EMA revises genotoxicity testing guidelines


The European Medicines Agency has published revised guidelinesĀ on how pharmaceutical companies should test their medicines for damaging effects on the DNA.

The guidelines set out best practice in genotoxicity testing and are expected to improve the assessment of the risks of human medicines.

Article continues below this sponsored advert
Cogora InRead Image
Join us at a one-day virtual cardiology event that will allow you to explore the latest advances in cardiovascular care. With the help of an advisory board of cardiology specialists we have put together an agenda tailored to multi-disciplinary teams - each talk is presented by an expert, or panel, who will share knowledge and case studies of relevance

The Agency also expects the implementation of the guidelines to reduce the number of animals used in the testing of medicines and to improve the efficiency of the medicine development process.

The guidelines were adopted by the Agency’s Committee for Medicinal Products for Human Use on 15 December 2011 and follow the core guidelines harmonised between Europe, Japan and the USA by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

The revised guidelines come into effect in June 2012.

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine